Yahoo India Web Search

Sign In

Search results

  1. www.aadibio.com › latest-newsInvestors & News - AADI Bioscience

    Apr 11, 2024 · Latest News. 11. Apr 2024. Evaluation of nab -sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines. 0 0. by AadiSite Support / April 11, 2024 / Publications.

  2. www.aadibio.com › aadi-bioscience-announces-closing-of-merger-with-aerpioAadi Bioscience Announces Closing of Merger with Aerpio...

    Aug 26, 2021 · LOS ANGELES, Ca.—August 26, 2021– Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously ...

  3. www.aadibio.com › aadi-bioscience-announces-fda-approval-of-its-first-productAadi Bioscience Announces FDA Approval of its First Product...

    Nov 23, 2021 · FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominance. FYARRO launch planned for Q1 2022; Investor call to be held today at 8:30 am ET.

  4. finance.yahoo.com › news › aadi-bioscience-reports-interim-results-210500054Aadi Bioscience Reports Interim Results from PRECISION1 Trial of...

    Dec 14, 2023 · Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway...

  5. finance.yahoo.com › news › aadi-bioscience-announces-closing-merger-200500624Aadi Bioscience Announces Closing of Merger with Aerpio...

    Aug 26, 2021 · LOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined...

  6. finance.yahoo.com › news › aadi-bioscience-announces-publication-long-210800607Aadi Bioscience Announces Publication of Long-Term Efficacy and...

    Mar 1, 2024 · Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, announced today that...

  7. www.prnewswire.com › news-releases › aadi-bioscience-announces-publication-of-longAadi Bioscience Announces Publication of Long-Term Efficacy and...

    Mar 1, 2024 · Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for cancers to bring transformational therapies to cancer patients with alterations in the mTOR pathway, a key...

  8. markets.businessinsider.com › news › stocksAadi Bioscience Appoints Dave Lennon, Ph.D. as President and...

    Oct 2, 2023 · Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer. Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development...

  9. markets.businessinsider.com › news › stocksAadi Bioscience Reports Interim Results from ... - Markets...

    Dec 14, 2023 · Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavil...

  10. stockanalysis.com › stocks › aadiAadi Bioscience, Inc. (AADI) Stock Price, Quote & News - Stock...

    Get a real-time Aadi Bioscience, Inc. (AADI) stock price quote with breaking news, financials, statistics, charts and more.